This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Altria's Q2 Earnings on the Deck: How to Play the Stock
by Swati Prasad
MO's Q2 results are likely to reflect NJOY ACE's market exit and soft cigarette volumes, though pricing strength may help.
Should Philip Morris Stock Be in Your Portfolio Ahead of Q2 Earnings?
by Swati Prasad
PM's second quarter results are likely to benefit from strong pricing and sustained smoke-free momentum despite currency pressures.
Altria Group Gains 21% in 6 Months: How to Play the Stock?
by Swati Prasad
MO is gaining ground with strong Marlboro pricing, smoke-free growth, and solid value, appealing to income-focused investors.
Philip Morris Gains 21% in 3 Months: How to Play the Stock?
by Swati Prasad
PM is gaining ground with smoke-free products and cost cuts, but regulatory and currency risks call for caution.
Will Altria's Smoke-Free Bets Deliver Long-Term Revenue Lift?
by Ansuiya Mohta
MO's on! pouches drive oral tobacco growth, but NJOY setbacks test its smoke-free strategy and future revenue outlook.
Philip Morris' Valuation Looks Overstretched: Time to Hit Pause?
by Zacks Equity Research
PM's smoke-free pivot fuels a 50% rally, but its stretched valuation may signal a pause for investors.
Altria Trades at a Bargain: Is it a Good Time to Buy the Stock?
by Ansuiya Mohta
MO trades at a steep discount to peers and shows bullish momentum, making it a potential value play in tobacco's shift to smoke-free.
Illicit E-Vapors Cloud Altira's Smoke-Free Ambitions: What's Next?
by Zacks Equity Research
MO's smoke-free push is under threat as illicit flavored e-vapor products dominate a growing U.S. nicotine market.
ZYN and IQOS Scale Up: Is Philip Morris Leading the Industry Reset?
by Ansuiya Mohta
PM sees smoke-free products drive 44% of Q1 profit as ZYN and IQOS momentum redefines its future beyond tobacco.
Altria's Smokeable Segment Shrinks: Is it Time to Pivot Faster?
by Ansuiya Mohta
MO's cigarette sales tumble amid inflation and rising e-vapor use, raising urgency for a faster smoke-free pivot.
British American Tobacco (BTI) Upgraded to Buy: Here's Why
by Zacks Equity Research
British American Tobacco (BTI) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Should Value Investors Buy British American Tobacco (BTI) Stock?
by Zacks Equity Research
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
Is Imperial Tobacco Group (IMBBY) Outperforming Other Consumer Staples Stocks This Year?
by Zacks Equity Research
Here is how Imperial Tobacco Group PLC (IMBBY) and British American Tobacco (BTI) have performed compared to their sector so far this year.
Philip Morris Stock Records 50% YTD Surge: Is it Too Late to Buy?
by Ansuiya Mohta
PM stock soars 50.1% year to date, fueled by smoke-free growth, premium pricing and bullish earnings momentum.
Is Altria's on! Pouch Gaining Enough Steam in Oral Tobacco?
by Ansuiya Mohta
With on! pouch shipments up and market share climbing, MO strengthens its position in smoke-free nicotine.
Can Smoke-Free Products Power Philip Morris' Next Decade of Growth?
by Zacks Equity Research
PM's smoke-free segment drives 33.1% gross profit growth in Q1, signaling a bold pivot beyond cigarettes.
Is Altria's Post Q1 Earnings Stock Dip a Green Light for Investors?
by Ansuiya Mohta
MO is backed by strong fundamentals, pricing power and long-term growth potential in smoke-free products.
PM Stock Up 6.9% Post Q1 Earnings: A Green Light for Investors?
by Ansuiya Mohta
PM shows strong growth prospects, driven by its successful shift to smoke-free products, solid first-quarter results and optimistic guidance.
Should Altria Stock Be in Your Portfolio Ahead of Q1 Earnings?
by Zacks Equity Research
MO's Q1 results are likely to reflect macroeconomic pressures and declining cigarette volumes, though growth in smoke--free products may help.
Altria Trading at a Discount: Should You Buy, Sell or Hold the Stock?
by Ansuiya Mohta
MO's low valuation reflects structural challenges, making it a risky bet amid declining volumes, regulatory pressure, and rising illicit competition.
MO Stock Up 5% in a Month: Lock in Gains or Hold for More Upside?
by Ansuiya Mohta
Altria's focus on innovation and its transition to reduced-risk products provide an upside, although risks from illicit market growth remain.
Is Altria Stock a Buy, Sell or Hold at a P/E Multiple of 10.29X?
by Ansuiya Mohta
MO presents an attractive valuation with growth potential. But investors should be cautious of challenges like increasing competition and declining cigarette shipments.
MO Stock Falls 4% in a Month: Is Now the Right Time to Buy?
by Ansuiya Mohta
MO's strong position in the smoke-free market, cost-savings and favorable earnings outlook position it as an attractive stock with growth potential.
Altria Stock Trading Cheaper Than Industry: What's the Next Best Move?
by Ansuiya Mohta
MO shows resilience through strategic partnerships and pricing power amid challenges from illicit products and declining cigarette volumes.
Altria Stock Reaches 52-Week High: Time to Capitalize or Wait?
by Ansuiya Mohta
Altria's smoke-free strategy and pricing power make it a compelling option for value-focused investors despite challenges from declining cigarette volumes.